New KDIGO Guideline For AKI

Continued from page 1

The guideline provides a clear definition and staging system for AKI and a comprehensive guide for proper classification and evaluation, prevention and treatment of AKI, including:


  • Diagnostic tools (urinary abnormalities, blood tests, biomarkers, imaging techniques)
  • Clinical settings to consider (community, in-hospital, ICU, developing countries)
  • Limitations (age, adults > 18 years, specific infectious and/or nephrotoxic insults)


  • Susceptible groups and risk factors (genetic, clinical, age, baseline eGFR)
  • General measures (volume status, hemodynamic monitoring, urine flow, renal perfusion)
  • Pharmacologic interventions (diuretics, vasopressors, vasodilators, acetylcysteine)
  • Measures to consider in the use of drugs and procedures associated with AKI

Treatment and Prognosis

  • Non-dialytic (volume, anti-sepsis, ventilation, metabolic control, euglycemia)
  • Dialytic (type, dose, initiation, discontinuation, anticoagulants, access)
  • Scoring systems (recovery, mortality)
  • The interrelationship between AKI and CKD
  • Factors that determine general and renal recovery and outcome

To view the complete guideline, please click here

KDIGO Guideline Development Process
KDIGO employs an evidence based approach that is modeled on the guideline development process used in the NKF Kidney Disease Outcome Quality Initiative (KDOQI™) guidelines. It empowers an independent work group supported by evidence review experts to rigorously examine the published evidence and formulate practice guidelines. Before they are finalized, the draft guidelines undergo a two-stage review process: internal review by the KDIGO Board, followed by open peer review by interested organizations, agencies and individuals worldwide. Reviewer comments are carefully reviewed by the work group, and incorporated as appropriate, before the guidelines are finalized and published.

KDIGO, a global non-profit foundation managed by the National Kidney Foundation, is dedicated to improving the care and outcomes of kidney disease patients worldwide through promoting coordination, collaboration, and integration of initiatives to develop and implement clinical practices guidelines.

For more information on KDIGO, please visit

« Previous12Next »
comments powered by Disqus